ROC-325 is an orally available novel inhibitor of lysosomal-mediated autophagy which diminishes AML cell viability with the IC50 range of 0.7-2.2 μM.

ROC-325 is an orally available novel inhibitor of lysosomal-mediated autophagy which diminishes AML cell viability with the IC50 range of 0.7-2.2 μM.

GDC-0575 is a potent and selective CHK1 inhibitor with an IC50 of 1.2 nM.

GDC-0575 is a potent and selective CHK1 inhibitor with an IC50 of 1.2 nM.

GSK2256098 is a potent, selective, reversible, and ATP competitive FAK kinase inhibitor with apparent Ki of 0.4 nM. GSK2256098 inhibits cancer cell growth and induces apoptosis.

GSK2256098 is a potent, selective, reversible, and ATP competitive FAK kinase inhibitor with apparent Ki of 0.4 nM. GSK2256098 inhibits cancer cell growth and induces apoptosis.

Compstatin binds to complement component C3 and inhibits complement activation with IC50 of 12 μM.

Compstatin binds to complement component C3 and inhibits complement activation with IC50 of 12 μM.

Compstatin binds to complement component C3 and inhibits complement activation with IC50 of 12 μM.

Senexin A is a potent and selective inhibitor of CDK8 and its nearest relative, CDK19 with Kd values of 0.83 μM and 0.31 μM for CDK8 and CDK19 ATP site binding, respectively.